Maxime Verhoeven

26 Chapter 2 Table 1 (continued) First author, publication year, reference Design Age in yrs. (SD) Female (%) RF+ (%) HAQ score (SD) Symptom duration in weeks (SD) DAS28 (SD) single csDMARD- initiating strategy N in single csDMARD- initiating strategy Remission- induction strategy N in remission- induction strategy Time of assess- ments in yrs. Treatment characteris- tics (both arms) Studies evaluating long-term effects of remission induction strategies (follow-up >4 years) Bergsma, 2017 33 RCT 55 (11) 55 61 1.3 (0.7) 21( § ) 4.2 (0.9) MTX+PBO 247 MTX+SSZ+GC 261 10 T2T bridg. 34w Emery, 2016 34 RCT § § § § § § MTX+PBO 160 GOL GOL(reduced dose)+MTX GOL+MTX 159 159 159 5 T2T Keystone, 2014 35 RCT § § § 1.3 (0.7) § 5.6 (1.7) MTX+PBO 164 ADA+MTX ADA+PBO 196 166 10 T2T Konijn, 2017 36 RCT 57 (13) 67 § § § § MTX+GC 81 MTX+SSZ+GC 81 4 T2T bridg. 34w Markusse, 2016 37 RCT 54 (14) 69 65 1.4 (0.7) 24( § ) 4.4 (0.9)** MTX MTX+GC 126 121 MTX+SSZ+GC INF+MTX 133 128 10 T2T bridg. 28w Verhoeven, 2018 38 RCT § § § § § § MTX+PBO 72 TCZ+MTX TCZ+PBO 75 79 5 T2T § = (spread of) variable not available; *= bDMARD based remission-induction strategy; **= DAS44(assessing 44 joints); reduced dose= 0.5 of normal dose; RF= rheumatoid factor; HAQ= health assessment questionnaire; DAS28= disease activity score assessing 28 joints; RCT= randomized controlled trial; bridg= bridging therapy; im= intramuscular ;iv= intravenous; Ada= adalimumab; BARI= baracitinib; CSA= cyclosporine; CZP= certolizumab pegol; ETN= etanercept; GC= glucocorticoid; GOL= golimumab; HCQ= hydroxychloroquine; INF= infliximab; Lef= leflunomide; MTX= methotrexate; PBO= placebo; SSZ= sulfasalazine; TCZ= tocilizumab; T2T= treat- to-target treatment strategy including step-up and step-down.